welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Amgen stock reverses after FDA puts one of its obesity treatments on clinical hold

Investor's Business Daily
Summary
Nutrition label

79% Informative

Amgen stock jumped more than 5% to 301.05 in morning trades on today 's stock market.

The company didn't specify the reason for the clinical hold, only saying "discussions are underway on a path forward to reopen the study" The disclosure isn't related to Amgen 's leading weight-loss drug, MariTide .

VR Score

84

Informative language

90

Neutral language

76

Article tone

formal

Language

English

Language complexity

37

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links